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Copyright © 2009 JCBN Summary Bay leaves (Laurus nobilis) have been shown to improve insulin function in vitro
but the effects on people have not been determined. The objective of this study was to determine
if bay leaves may be important in the prevention and/or alleviation of type 2 diabetes. Forty
people with type 2 diabetes were divided into 4 groups and given capsules containing 1, 2 or
3 g of ground bay leaves per day for 30 days or a placebo followed by a 10 day washout period.
All three levels of bay leaves reduced serum glucose with significant decreases ranging from
21 to 26% after 30 d. Total cholesterol decreased, 20 to 24%, after 30 days with larger
decreases in low density lipoprotein (LDL) cholesterol of 32 to 40%. High density lipoprotein
(HDL) cholesterol increased 29 and 20% in the groups receiving 1 and 2 g of bay leaves,
respectively. Triglycerides also decreased 34 and 25% in groups consuming 1 and 2 g of bay
leaves, respectively, after 30 d. There were no significant changes in the placebo group. In
summary, this study demonstrates that consumption of bay leaves, 1 to 3 g/d for 30 days,
decreases risk factors for diabetes and cardiovascular diseases and suggests that bay leaves
may be beneficial for people with type 2 diabetes.
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Introduction
Diabetes mellitus is a chronic disorder of glucose metabo-
lism resulting from dysfunction of pancreatic beta cells and
insulin resistance. The incidence of cardiovascular diseases
is increased two- to four-fold in people with type 2 diabetes
[1]. Although the causes of type 2 diabetes and cardio-
vascular diseases are multifactorial, diet definitely plays a
role in the incidence and severity of these diseases. The
dietary components beneficial in the prevention and treat-
ment of these diseases have not been clearly defined, but it is
postulated that spices may play a role. Spices that have been
reported to be hypoglycemic include fenugreek, garlic,
turmeric, cumin, ginger, mustard, curry and coriander [2].
We have also shown that spices such as cinnamon, cloves,
bay leaves, and turmeric display insulin-enhancing activity
in vitro [3]. Botanical products can improve glucose metabo-
lism and the overall condition of individuals with diabetes
not only by hypoglycemic effects but also by improving
lipid metabolism, antioxidant status, and capillary function
[4].
Based on our in vitro studies, we tested the effects of
cinnamon on people with type 2 diabetes [5], the metabolic
syndrome [6] and polycystic ovary syndrome and demon-
strated that cinnamon or dried aqueous extracts of cinnamon
improve glucose and insulin metabolism and circulating
blood lipids. Similar properties were expected for bay leaves
since cinnamon and bay leaves have similar effects in vitro
on insulin action [3, 7]. Therefore, this study was designedBay Leaves Improve Glucose and Lipids
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to determine whether there is a dose response of bay leaves
on clinical variables associated with diabetes and cardio-
vascular diseases in patients with type 2 diabetes.
Materials and Methods
This study was conducted in the Department of Human
Nutrition, Agricultural University Peshawar, (NWFP)
Pakistan. The study was approved by the Ethics Committee
and Human Studies Review Board of the University.
Selection criteria for the study were that the participating
individuals have type 2 diabetes, 40 years old or more, not
on insulin therapy and not taking medicines for other health
conditions. Subjects were excluded from the study if they
had a body mass index greater than 35 kg/m2, or a history of
musculoskeletal, autoimmune or neurologic disease. A total
of 40 individuals with type 2 diabetes, 18 men and 22
women, were selected for the study and were divided
randomly into four groups and given capsules containing
one, two or three g of ground bay leaves or a placebo daily.
Subjects were instructed not to change their normal daily
routine including medications, foods, and exercise activities.
Bay Leaves (Laurus nobilis) and placebo (corn flour)
were ground finely and put into capsules (Noor Drug
Agency, Peshawar, Pakistan). Each capsule contained either
500 mg of bay leaves or corn flour. The study was conducted
for 40 days, 30 days for bay leaves/placebo and 10 days for
washout period. Group 1 consumed 1 g dose or 2 capsules of
bay leaves per day, one after breakfast and the other after
dinner. Group 2 consumed 2 g dose, 2 capsules after break-
fast and 2 after dinner. Group 3 consumed 3 g dose, 3
capsules after breakfast and 3 capsules after dinner. Group 4
consumed 2 capsules of placebo per day, one after breakfast
and the other after dinner. The subjects were instructed to
take the capsules immediately after meals. Subjects were
selected randomly and were not part of a group and were
not directly in contact with each other. Compliance was
monitored by capsule count and contact with the subjects.
Compliance was considered excellent as all capsules were
consumed and subjects reported no significant side effects.
Subjects continued their normal diets and their diabetic
medications throughout the study. The subjects were taking
sulfonylurea and metformin drugs. Subjects were not on
statin drugs. The medications were not changed during the
study.
On days 0, 10, 20, 30 and 40, 5 ml of fasting blood were
collected from each subject. Blood samples were transferred
to sterilized centrifuge tubes. The blood samples were
centrifuged for 10 min in a tabletop clinical centrifuge at
4,000 rpm for serum separation. Serum samples were stored
in a freezer at 0°C for later analyses.
Glucose was determined by the method of Barham et al.
[8], triglycerides by the method of Werner et al. [9] and
cholesterol was determined by the method of Allain et al.
[10] using kits that are commercially available. Low
density lipoprotein (LDL) cholesterol was precipitated by
adding phosphotungstic acid and magnesium ions to the
sample. Centrifugation left only the high density lipoprotein
cholesterol (HDL) in the supernatant [11] and, then by the
above mentioned cholesterol determination method, HDL
was measured. LDL cholesterol was calculated by sub-
tracting collectively the triglycerides/5 and HDL cholesterol
from total cholesterol [12].
Two-way ANOVA and randomized complete block
design were used for statistical analyses [13]. Values given
are means ± standard deviations. Sample size was selected
based upon our previous study for cinnamon and blood
glucose [5]. With a difference in means of 2.0 mmol/L, SD
of 1.3 with four groups of 10 subjects, the power is 0.8
(SigmaStat 3.1, SPSS Inc., Chicago, IL).
Results
All three levels of bay leaves tested led to decreased
fasting serum glucose (Table 1) ranging from 21 to 26%
after 30 days. Values for subjects consuming 1 and 3 g per
day were significant after 10 days while those in the 2 g
group were not significant until 30 days. Fasting glucose of
Table 1. Bay leaves decrease serum glucose in subjects with type 2 diabetes
Values are means ± SD for 10 subjects per treatment.
Means in the same row, with different superscripts, are significantly different at p<0.05. Clarification of the different means is further
illustrated in bottom of Table 2.
Doses of bay leaves 
and placebo (g/day)
Fasting serum glucose (mmol/L)
Before intake 
of bay leaves
During intake of bay leaves
After intake 
of bay leaves
Day 0 Day 10 Day 20 Day 30 Day 40
Bay Leaves 1 12.0 ± 3.6a 9.0 ± 2.4c 10.4 ± 3.5b 8.9 ± 2.6c 10.2 ± 2.7b
Bay Leaves 2 11.3 ± 3.5a 11.0 ± 3.2a 10.2 ± 3.4a 8.8 ± 2.3b 10.5 ± 3.8a
Bay Leaves 3 16.9 ± 4.2a 13.3 ± 3.9b 14.0 ± 2.7b 13.4 ± 2.7b 14.0 ± 3.1b
Placebo 1 9.7 ± 4.1a 10.3 ± 5.2a 9.3 ± 3.8a 9.3 ± 3.9a 9.4 ± 3.7aA. Khan et al.
J. Clin. Biochem. Nutr.
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the subjects who consumed 1 and 3 g of bay leaves per day
also remained significantly lower on day 40 (10 days) after
stopping the intake of the capsules) while those of the 2 g
group were not significantly lower after the 10 days washout
period. There were no significant changes in the placebo
group at any of the time points. It should be noted that the
reductions in glucose given in Table 1 and other variables in
the following tables are in addition to those due to medica-
tion since all subjects continued taking their usual diabetic
medicine during the study. There were no significant sex by
treatment interactions.
Serum cholesterol also decreased from 21 to 24% in
people with type 2 diabetes consuming 1, 2 or 3 g of bay
leaves after 20 days. Values were significant after only 10
days in subjects consuming 2 and 3 g per day. Values
remained significantly lower after the 10 washout period
only in the group consuming 3 g per day (Table 2). There
were no significant changes in the placebo group at any of
the time points (Table 2).
The largest decrease in cholesterol was in the LDL
cholesterol with decreases of 32 to 40% after 30 days and
decreases in all three groups were significant after only 20
days (Table 3). LDL cholesterol of subjects consuming 3 g
of bay leaves per day remained 35% lower even after the 10
day washout period.
There were also positive effects on HDL cholesterol with
increases of 29 and 19% in subjects taking 1 and 2 g of bay
leaves per day, respectively, after 30 days. Increases were
not significant in the group taking 3 g per day but the base-
line of this group of subjects was 0.26 mol/L (10 mg/dl) or
more higher than those of either of the groups consuming 1
or 2 g of bay leaves. There were no significant changes in
the placebo group (Table 4).
Bay leaves also reduced serum triglycerides (Table 5).
One and 2 g doses of bay leaves reduced triglycerides 33 and
25%, respectively, after 30 days. Reductions in the subjects
consuming 3 g of bay leaves were variable with significant
reductions after 10 days but not after 20 or 30 days but
decreases were again significant after the 10 day washout
period (Table 5).
Discussion
This study demonstrates beneficial effects of low levels
(1–3 g per day) of bay leaves on glucose, total cholesterol,
LDL cholesterol, HDL cholesterol and triglycerides in
subjects with type 2 diabetes. It is not clear whether even
less than 1 g of bay leaves per day would also be beneficial.
Table 2. Bay leaves decrease serum cholesterol in subjects with type 2 diabetes
Conditions defined in Table 1. Means in the same row, with different superscripts, are significantly different at p<0.05.
For example, the mean of 6.34 ± 2.69a is not different from 5.40 ± 2.74abc and 5.97 ± 1.63ab (all three contain a superscript (a)) but is
different from 5.09 ± 1.63bc and 4.84 ± 1.55c. Similarly, mean values with common superscripts b and or c are also not significantly
different.
Doses of bay leaves 
and placebo (g/day)
Fasting serum cholesterol (mmol/L)
Before intake 
of bay leaves
During intake of bay leaves
After intake 
of bay leaves
Day 0 Day 10 Day 20 Day 30 Day 40
Bay Leaves 1 6.34 ± 2.69a 5.40 ± 2.74abc 5.09 ± 1.63bc 4.84 ± 1.55c 5.97 ± 1.63ab
Bay Leaves 2 5.77 ± 1.16a 4.58 ± 0.98b 4.34 ± 0.88b 4.60 ± 1.03b 5.59 ± 1.22a
Bay Leaves 3 5.84 ± 1.81a 5.04 ± 1.66b 4.47 ± 1.58b 4.63 ± 1.22b 4.42 ± 0.96b
Placebo 1 5.74 ± 0.70a 5.72 ± 1.03a 5.66 ± 0.57a 5.90 ± 0.67a 5.59 ± 0.72a
Table 3. Bay leaves decrease serum LDL cholesterol in subjects with type 2 diabetes
Conditions defined in Table 1.
Doses of bay leaves 
and placebo (g/day)
Fasting Serum LDL (mmol/L)
Before intake 
of bay leaves
During intake of bay leaves
After intake 
of bay eaves
Day 0 Day 10 Day 20 Day 30 Day 40
Bay Leaves 1 3.67 ± 2.38a 2.92 ± 2.69ab 2.30 ± 1.27b 2.38 ± 1.68b 3.52 ± 1.55a
Bay Leaves 2 3.18 ± 0.85a 2.97 ± 0.88b 1.97 ± 0.85b 2.15 ± 0.75b 3.21 ± 0.98a
Bay Leaves 3 3.10 ± 1.22a 2.61 ± 1.24a 1.99 ± 1.03b 1.89 ± 0.72b 1.99 ± 0.78b
Placebo 1 3.41 ± 0.49a 3.44 ± 0.85a 3.36 ± 0.59a 3.57 ± 0.47a 3.41 ± 0.75aBay Leaves Improve Glucose and Lipids
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There was no dose response between 1 and 3 g daily of bay
leaves as responses at all three levels were similar. The
maintenance of lower serum glucose and lipid levels, even
when the individuals were not consuming bay leaves for 10
days, denotes sustained effects of bay leaves, indicating that
bay leaves would not need to be consumed every day. The
data are also reinforced by the observation that there were no
significant changes in the placebo group. There were also no
problems with compliance or problems associated with the
consumption of 1 to 3 g of bay leaves per day.
The randomization of the groups resulted in the group that
received 3 g of bay leaves per day to have significantly
higher HDL levels, at the onset of the study, than the groups
that received either 1 or 2 g of bay leaves and is likely the
reason why there were no significant effects on the HDL of
this group of subjects. A study with larger numbers of
subjects is needed to confirm the lack of an improvement in
the group that received 3 g of bay leaves on HDL. There is
no reason to assume that the effects of 3 g of bay leaves on
HDL would not also be positive and be similar to the effects
of 1 and 2 grams per day.
The active components of bay leaves are under study. Of
the 81 compounds representing 98.74% of total oil of Laurus
nobilis, monocyclic monoterpenes such as 1,8-cineole
(58.59%), alpha-terpinyl acetate (8.82%), and terpinene-4-ol
(4.25%) are the main components. Bicyclic monoterpenes
such as alpha- and beta-pinene (3.39–3.25%) and sabinene
(3.32%) are also present. The acyclic monoterpenes,
linalool, myrcenol, and sesquiterpenes are found at less
than 0.5%. o-Cymene (1.30%) and p-cymene (1.83%) are
also present, and cumin aldehyde, dimethylstyrene, eugenol,
methyl eugenol, and carvacrol are minor, aromatic com-
pounds of laurel oil [14]. The active in vitro component of
bay leaves is water soluble [3, 7] and is likely not a compo-
nent of the total oil. Ground cinnamon, has in vivo insulin
enhancing activity in experimental animals [15–17] and hu-
mans [5, 18]. However, cinnamon oil does not display in
vitro insulin enhancing activity while the water soluble
compounds found in cinnamon do display biological activity
[3, 7, 19]. Dried aqueous extracts of cinnamon also improve
glucose and lipid metabolism in experimental animals [15–
17, 20, 21]. Similarly, aqueous extracts of cloves display in
vitro insulin enhancing activity but clove oil is devoid of
activity [3, 7, 19].
The active component of the bay leaves is likely a
polyphenol since more than 80% of the in vitro insulin
potentiating activity was removed by polyvinylpyrrolidone
[7], which binds aromatic hydroxyl groups [22].
The mechanisms of the effects of cloves on glucose and
lipid concentrations likely involve improvements in insulin
sensitivity which would lead to improvements in glucose
and blood lipids [1]. Polyphenols found in cinnamon appear
to function similarly to the bioactive components in bay
leaves; cinnamon compounds have been shown to have
Table 4. Bay leaves increase serum HDL cholesterol in subjects with type 2 diabetes
Conditions defined in Table 1.
Doses of bay leaves 
and placebo (g/day)
Fasting serum HDL cholesterol (mmol/L)
Before intake 
of bay leaves
During intake of bay leaves
After intake 
of bay leaves
Day 0 Day 10 Day 20 Day 30 Day 40
Bay Leaves 1 1.24 ± 0.28c 1.40 ± 0.28bc 1.50 ± 0.26ab 1.60 ± 0.31a 1.47 ± 0.28ab
Bay Leaves 2 1.14 ± 0.36b 1.29 ± 0.34ab 1.37 ± 0.34a 1.37 ± 0.28a 1.19 ± 0.34b
Bay Leaves 3 1.50 ± 0.41a 1.42 ± 0.34a 1.40 ± 0.44a 1.58 ± 0.41a 1.55 ± 0.44a
Placebo 1 1.27 ± 0.26ab 1.22 ± 0.26b 1.34 ± 0.26a 1.22 ± 0.21b 1.16 ± 0.21b
Table 5. Bay leaves decrease serum triglycerides in subjects with type 2 diabetes
Conditions defined in Table 1.
Doses of bay leaves 
and placebo (g/day)
Fasting serum triglycerides (mmol/L)
Before intake 
of bay leaves
During intakes of bay leaves
After intake 
of bay leaves
Day 0 Day 10 Day 20 Day 30 Day 40
Bay Leaves 1 3.13 ± 1.48a 2.38 ± 2.00bc 2.81 ± 1.38ab 2.09 ± 1.07c 2.16 ± 0.85c
Bay Leaves 2 3.17 ± 2.10a 2.71 ± 1.66ab 2.20 ± 0.96b 2.39 ± 1.31b 2.57 ± 1.55b
Bay Leaves 3 2.65 ± 1.08a 2.19 ± 0.90bc 2.33 ± 0.79abc 2.54 ± 1.28ab 1.93 ± 0.87c
Placebo 1 2.37 ± 0.91a 2.30 ± 0.84a 2.09 ± 0.79a 2.38 ± 0.88a 2.18 ± 0.70aA. Khan et al.
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effects on insulin sensitivity, glucose uptake, antioxidant
status, inflammatory response, and glucose emptying [23].
In summary, bay leaves reduced serum glucose, total
cholesterol, LDL cholesterol and triglycerides, and increased
HDL cholesterol levels in people with type 2 diabetes.
Additional studies are needed to confirm these results and
also to identify the active components.
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